Global Glycopeptide Antibiotics Market, By Drugs (Vancomycin, Dalbavancin, Oritavancin, Others), Indication (Skin and Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Glycopeptide Antibiotics Market Analysis and Size
Growing incidence of cancer and other infectious diseases are anticipated to increase the growth during the forecast period. The common glycopeptides that are currently used in clinical practice to treat enterococcal infections are teicoplanin and vancomycin. The growth of glycopeptide antibiotics market is increased by the growing cases of numerous infectious diseases and emerging launches in research and development activities that are conducted by many pharmaceuticals’ companies.
Data Bridge Market Research analyses a growth rate in the glycopeptide antibiotics market in the forecast period 2023-2030. The expected CAGR of glycopeptide antibiotics market is tend to be around 10% in the mentioned forecast period. The market was valued at USD 3.07 billion in 2022, and it would grow up to USD 6.6 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Glycopeptide Antibiotics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Vancomycin, Dalbavancin, Oritavancin, Others), Indication (Skin and Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
ANI Pharmaceuticals, Inc. (U.S.), Fresenius SE & Co. KGaA (Germany), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (U.S.), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), Allergan (U.S.), Melinta Therapeutics, Inc (U.S.), Cumberland Pharmaceuticals Inc (U.S.), Theravance Biopharma (U.S.), Janssen Global Services, LLC (U.S.), Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline plc. (U.K.), Bayer AG (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Glycopeptide antibiotics are the kind of antibiotic which obstructs bacterial cell wall formation by restricting peptidoglycan synthesis. They are widely used for the treatment of multi-resistant Staphylococcus aureus (MRSA) infections and other enterococcal infections, which are unaffected to beta-lactams and other antibiotics. They are also used in cases where there is an allergy to beta-lactams.
Global Glycopeptide Antibiotics Market Dynamics
Drivers
- Rising Cases of Cancer and Infectious Diseases
Growing cancer and other infectious diseases are anticipated to boost the market growth during the forecast period 2023-2030. For instance, according to the CDC reports U.S, 1,752,735 new cancer cases combined with 599,589 deaths were observed in 2019. Additionally, according to the records of Globocan 2020, U.K., around 457,960 new cases with 179,648 deaths were reported in 2020. As per the reports, the most common types of malignancies observed were breast, prostate cancer and Non-Hodgkin’s lymphoma. Thus, this growing incidence is demanding higher rate of antibiotics and thus boosting the market growth.
- Increased Collaborations and Acquisitions
Several collaborations associated with the glycopeptide antibiotics are increasing the market growth. For instance, AbbVie Inc got U.S. FDA approval for DALVANCE in July 2021 for the treatment of acute bacterial skin and other skin structure infections in pediatric patients since birth. Additionally, Sandoz International GmbH launched Daptomycin injection 500 mg, in the U.S. market in July 2020, for treating complicated skin and skin structure infections and numerous type of bloodstream infections. Thus, it boost the market growth.
Opportunities
- Increasing Demand of Retail Pharmacies
The increase in the number of narcotic drugs which is delivered through retail pharmacies and the rise in the number of retail pharmacies in developing and developed countries create opportunities for the market growth. Additionally, patients choose retail pharmacies for purchasing drugs, as these are easily available.
- Higher Efficiency of Novel Drugs
The efficiency of several existing products is anticipated to result into increasing revenues due to doctor recommendations. For instance, BLEOMYCIN for injection USP is the mixture of cytotoxic glycopeptide antibiotics which is isolated from Streptomyces verticillus and is widely used for the treatment of testicular carcinoma, squamous cell carcinoma, and various types of lymphomas.
Restraints/Challenges
- High Cost of Treatment
The increased cost which is required for the numerous treatment methods hinders market growth. Numerous market players make some huge investments in manufacturing advanced treatment procedures to increase the recovery process, and in return, the cost is increased.
This glycopeptide antibiotics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the glycopeptide antibiotics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Glycopeptide Antibiotics Market Scope
The glycopeptide antibiotics market is segmented on the basis of drugs, indication, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Vancomycin
- Dalbavancin
- Oritavancin
- Others
Indication
- Skin and Structure Infection
- Meningitis
- Clostridioides Difficile Infection
- Enterocolitis
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Glycopeptide Antibiotics Regional Analysis/Insights
The glycopeptide antibiotics market is analyzed and market size insights and trends are provided by drugs, indication, route of administration, end-users and distribution channel as referenced above.
The major countries covered in the glycopeptide antibiotics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market because of the increasing occurrence of asthma, and severe pain and increased drug abuse.
Asia-Pacific is considered to grow over the coming years because of the attracting attention of major market players to establish many emerging economics with significant growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Glycopeptide Antibiotics Share Analysis
The glycopeptide antibiotics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to glycopeptide antibiotics market
Key players operating in the glycopeptide antibiotics market include:
- ANI Pharmaceuticals, Inc. (U.S.)
- Fresenius SE & Co. KGaA (Germany)
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Novartis AG (U.S.),
- Hikma Pharmaceuticals plc (U.K.)
- Aurobindo Pharma (India)
- Abbvie, Inc (U.S.)
- Melinta Therapeutics, Inc (U.S.)
- Cumberland Pharmaceuticals Inc (U.S.)
- Theravance Biopharma (U.S.)
- Janssen Global Services, LLC (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (U.S.)
SKU-